Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
about
Concepts of immunotherapy for gliomaA nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastomaGenetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.Anti-tumoral effects of miR-3189-3p in glioblastomaSulforaphane induces apoptosis and inhibits invasion in U251MG glioblastoma cells.Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastomaAgonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomideAnti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapyInvestigating the impact of headaches on the quality of life of patients with glioblastoma multiforme: a qualitative study.MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.Par-4 as a potential target for cancer therapy.Interleukins in glioblastoma pathophysiology: implications for therapy.Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.The future of glioblastoma therapy: synergism of standard of care and immunotherapy.HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.Immunological Aspects of Malignant Gliomas.TGF-β Regulates Survivin to Affect Cell Cycle and the Expression of EGFR and MMP9 in Glioblastoma.Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of glioblastoma.Differential Effects of MicroRNAs on Glioblastoma Growth and Migration.Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy.Antagonism of NF-κB-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD)-anti-NF-κB vs. anti-miRNA strategies.Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
P2860
Q28083888-3D0F0D4B-EAC7-49D5-ACD9-A03392C14136Q30412393-AB5658CE-D431-4B1F-AF25-7C868E0E9D02Q34076281-B2C1585C-8D51-4144-A4E6-7D28672EAFAFQ34346483-4ECE4589-55B6-459E-AFAE-3953AB33B9DBQ34943946-1A260F95-9CF1-4F17-87B7-EF9DF3C1C7F9Q34973753-63FE1F95-DAA4-4F9D-95A3-7D205D61417DQ35088396-55EED005-09F9-44FA-8E95-A09D51C94933Q35221508-A2FB072D-A386-4A26-81B3-56BAA2740C82Q35973580-748545FE-D697-4978-92B8-E6772FEFD739Q36145632-2991A7CD-209D-492F-90EA-1A021CF93929Q36907372-5ADFDB47-C6D0-4123-B785-1604CB959B2FQ37220522-DFF248B6-D2E5-460A-91C6-1D32C945EA15Q37288597-107A4A7F-310D-42E8-A3C3-7F68FF324C40Q37301832-DD9B9CEC-F333-40F6-87B6-B94C573A22A7Q37454496-3D317B67-6653-4C71-B5BE-79EF62ECAA6BQ37694818-6892AA88-F9EF-4513-AC52-053725BF06C7Q38051738-10A69A23-CC3F-4867-AED9-EBFA368EFA18Q38051761-5D742F01-EBA3-4E96-87BB-2318FD5BDA96Q38110540-D61BCC08-095B-41EE-AC70-D9B809246EFEQ38170398-C260C6D2-4AE7-4D5A-B8BB-5463D6EDDA3DQ38255481-3DD7ECB1-F5BE-4B88-9871-74310E8EE59BQ38387230-9D29141F-DC41-48E3-AD21-2A1E4506CBFDQ38870994-71A7C14E-7F96-4790-8E3A-6A37DF809F5DQ38909514-FE5B908C-F9C3-4D69-BC56-324F690EE0BEQ38926305-FFA479BA-9F97-4BAA-BF46-7906D3BA216AQ39197715-8D2D1FE6-949E-4A40-AB52-E28043F16451Q39219681-79FFF6D6-D357-4873-8A4F-F483E6CABFD9Q39475989-C2E608A9-27AE-4BFA-96CA-2412DA076EB4Q39640321-266FD947-0C5E-4331-9C57-F000F2E6C517Q40247856-458201CA-0EA5-4E33-B2D5-F8D6822B076DQ48311392-A220923D-3CD1-412D-A365-4D9CA23C65BC
P2860
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
@en
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
@nl
type
label
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
@en
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
@nl
prefLabel
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
@en
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
@nl
P2093
P1476
Temozolomide and other potential agents for the treatment of glioblastoma multiforme
@en
P2093
Andrew Yew
Daniel T Nagasawa
Frances Chow
Nicole Cremer
P304
307-22, ix
P356
10.1016/J.NEC.2012.01.007
P577
2012-04-01T00:00:00Z